ArticleFrontiers in aging neuroscience2025
Multimodal DTI-ALPS and hippocampal microstructural signatures unveil stage-specific pathways in Alzheimer's disease progression.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Imaging biomarkers of glymphatic system dysfunction in Alzheimer's disease: a systematic review and meta-analysis with a focus on DTI-ALPS index.Frontiers in aging neuroscience · 2026Pooled it
- Glymphatic dysfunction in Alzheimer's disease: a systematic review and meta-analysis of the DTI-ALPS index as an imaging biomarker.Frontiers in aging neuroscience · 2026Pooled it
- Rational drug design and synthesis of novel bioactive molecules with oxygen heterocycles, including AChE and BChE inhibitory properties and SAR studies.Molecular diversity · 2026Review
- The Role of PGC-1α in Neurodegenerative Diseases: Molecular Mechanisms, Translational Challenges, and Therapeutic Potential.Molecular neurobiology · 2026Review
- Multidimensional Prosodic and Semantic Coherence Modeling for Mandarin Mild Cognitive Impairment Detection.Bioengineering (Basel, Switzerland) · 2026Article
- Physical exercise as a non-pharmacological strategy to enhance glymphatic function.IBRO neuroscience reports · 2026Review
- Bridging neuroinflammation, oxidative stress, and neurogenesis: aromatic turmerone as a multifunctional modulator via NF-κB and Nrf2 pathways.Inflammopharmacology · 2026Review
- A Consolidated Framework for the Detection of Alzheimer's Disease Using EEG Signals and Hybrid Models.Biomimetics (Basel, Switzerland) · 2026Article
- Article
- DTI-ALPS Is Associated with Temporolimbic Amyloid but Not Plasma p-Tau181 Across the Alzheimer's Disease Continuum.Research square · 2026Article
- Multi-Target-Directed Ligands (MTDLs) as Potential Therapeutic Candidates Targeting Multiple Pathogenic Factor of Alzheimer's Disease.CNS neuroscience & therapeutics · 2026Review
- Interpretable CRAM‑Enhanced Lightweight Dual‑Branch CNN for Real‑Time Breast Cancer Histopathology in Internet‑of‑Medical‑Things Environments.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Neurovascular Uncoupling in Alzheimer's and Parkinson's Diseases: Mechanisms and Therapeutic Strategies.Brain sciences · 2026Review
- Epigenetic and Transcriptomic Pathways Underlying Animal Models of Cognitive and Psychiatric Disorders: A Scoping Review.Current issues in molecular biology · 2026Review
- Metabolic reprogramming of neurons in alzheimer disease: a biochemical perspective.Metabolic brain disease · 2026Review
- The dual face of human chorionic gonadotropin in the CNS: neuroprotection, signaling, and possible pathological effects.Archives of gynecology and obstetrics · 2026Review
- Smart Biosensing Nanomaterials for Alzheimer's Disease: Advances in Design and Drug Delivery Strategies to Overcome the Blood-Brain Barrier.Biosensors · 2026Review
- Structural changes in gray matter and white matter across the Alzheimer's disease continuum.Frontiers in neuroscience · 2026Article
- Multimodal AI fusion: integrating MRI with PET/CT, histopathology, and liquid biopsy for bone tumor diagnosis.Frontiers in oncology · 2026Review
- Mitochondrial dysfunction in Alzheimer's disease: connecting pathophysiology with neuroimaging.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Develop a multimodal biomarker framework integrating DTI-ALPS (Diffusion Tensor Imaging along the Perivascular Space), hippocampal diffusivity, and CSF profiles for staging Alzheimer's disease (AD) progression across the HC → MCI → AD continuum. Methods: Cross-sectional analysis of 60 age-matched participants [18 healthy controls (HC), 20 with mild cognitive impairment (MCI), and 22 with Alzheimer's disease (AD)] combining 3 T MRI-derived biomarkers (bilateral hippocampal fractional anisotropy (FA) and mean diffusivity (MD), and DTI-ALPS). Cerebrospinal fluid (CSF) analysis (Aβ42, p-tau181, t-tau), and cognitive assessments (MMSE, MoCA). Statistical analyses included ANOVA with Bonferroni correction, Pearson correlations, and ROC curve evaluation for disease classification. Results: DTI-ALPS exhibited a progressive decline (HC: 1.31 ± 0.12 → MCI: 1.26 ± 0.09 → AD: 0.87 ± 0.19; Conclusion: The framework reveals distinct biomarker trajectories: DTI-ALPS distinguishes symptomatic AD from preclinical stages, while right hippocampal MD progression reflects tau-mediated neurodegeneration. Early FA reductions in MCI combined with CSF profiles suggest a hierarchical staging model: amyloid-associated perivascular dysfunction is associated with asymmetric tau-driven hippocampal degeneration. This multimodal approach provides clinically actionable biomarkers for AD progression monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.